HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Intensified conditioning regimen allo-HSCT is based on a hypothesis of that intensifying
condition with less-used drugs could overcome resistance,reduce tumor burden, and most
importantly, spare enough time for slow-growing GVL effect following immune reconstitution to
finally get rid of MRD and control the disease. Our previous trial of HDE-ALL-2011
(NCT01457040) have confirmed the role of intensified conditioning allo-HSCT in adult ALL,
resulting in significantly improved OS and EFS in comparison with previous standard TBI/CY2
conditioning regimen(data not yet published). But at the same time, FA-TBI/CY2-VP16
conditioning regimen was associated with high transplantation-related mortality (TRM), which
might be attributed to excessive suppression on both bone marrow and immune. TT-ALL-HIE-2013,
substituting FA with idarubicin, is aimed at maintaining anti-tumor effect with less
cross-resistance and immune suppression and reducing TRM.